Your browser is no longer supported. Please, upgrade your browser.
Settings
CBLI Cleveland BioLabs, Inc. daily Stock Chart
CBLI [NASD]
Cleveland BioLabs, Inc.
Index- P/E- EPS (ttm)-0.33 Insider Own3.83% Shs Outstand11.19M Perf Week0.30%
Market Cap37.26M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float4.71M Perf Month-12.60%
Income-3.70M PEG- EPS next Q- Inst Own2.40% Short Float5.27% Perf Quarter113.46%
Sales3.30M P/S11.29 EPS this Y86.50% Inst Trans-6.93% Short Ratio0.18 Perf Half Y113.46%
Book/sh0.54 P/B6.17 EPS next Y- ROA-22.50% Target Price2.00 Perf Year32.14%
Cash/sh1.17 P/C2.84 EPS next 5Y- ROE-48.50% 52W Range1.22 - 5.55 Perf YTD134.51%
Dividend- P/FCF- EPS past 5Y37.10% ROI-84.70% 52W High-40.00% Beta0.23
Dividend %- Quick Ratio5.20 Sales past 5Y-16.70% Gross Margin- 52W Low172.95% ATR0.25
Employees15 Current Ratio5.20 Sales Q/Q-25.00% Oper. Margin- RSI (14)43.03 Volatility4.72% 6.62%
OptionableNo Debt/Eq0.00 EPS Q/Q-149.10% Profit Margin- Rel Volume0.04 Prev Close3.33
ShortableYes LT Debt/Eq0.00 EarningsMay 22 BMO Payout- Avg Volume1.37M Price3.33
Recom3.00 SMA20-6.15% SMA50-7.07% SMA20057.66% Volume50,192 Change0.00%
Jan-24-14Downgrade Oppenheimer Outperform → Perform
Mar-21-13Initiated Cantor Fitzgerald Buy $4
Dec-06-12Initiated Oppenheimer Outperform $3
Dec-04-12Initiated Burrill Institutional Research Mkt Outperform $4
Feb-02-11Initiated Wedbush Outperform $10
Oct-13-10Downgrade WBB Securities Strong Buy → Hold $6.50 → $6.50
Sep-17-10Reiterated Rodman & Renshaw Mkt Outperform $8 → $11
Jul-21-10Downgrade WBB Securities Strong Buy → Speculative Buy $6.50
Sep-29-09Initiated Rodman & Renshaw Mkt Outperform $8
Jun-26-17 03:32PM  ETFs with exposure to Cleveland BioLabs, Inc. : June 26, 2017 Capital Cube
Jun-16-17 03:31PM  ETFs with exposure to Cleveland BioLabs, Inc. : June 16, 2017 Capital Cube
Jun-05-17 02:06PM  ETFs with exposure to Cleveland BioLabs, Inc. : June 5, 2017 Capital Cube
Jun-02-17 10:27AM  Cleveland BioLabs, Inc. :CBLI-US: Earnings Analysis: Q1, 2017 By the Numbers : June 2, 2017 Capital Cube
May-15-17 07:30AM  Cleveland BioLabs Reports First Quarter 2017 Financial Results and Development Progress Marketwired
Apr-20-17 08:00AM  Governments Looking at Cleveland Biolabs Radiation Countermeasure Accesswire -16.27%
Apr-19-17 02:14PM  ETFs with exposure to Cleveland BioLabs, Inc. : April 19, 2017 Capital Cube +46.13%
Apr-18-17 07:30AM  Today's Research Reports on Biotech Stocks to Watch: Cleveland BioLabs and Infinity Pharmaceuticals Accesswire -27.29%
Apr-17-17 07:36AM  Cleveland BioLabs Announces Commencement of In Vivo Biocomparability Study Marketwired +207.69%
07:30AM  Cleveland BioLabs Announces European Medicines Agency Positive Opinion Regarding the Entolimod Pediatric Investigation Plan Marketwired
Apr-11-17 05:00PM  Cleveland BioLabs Announces Webcast of Annual Meeting Marketwired
Apr-07-17 04:05PM  ETFs with exposure to Cleveland BioLabs, Inc. : April 7, 2017 Capital Cube
Mar-17-17 12:04PM  Cleveland BioLabs, Inc. :CBLI-US: Earnings Analysis: Q4, 2016 By the Numbers : March 17, 2017 Capital Cube
12:04PM  Cleveland BioLabs, Inc. :CBLI-US: Earnings Analysis: Q4, 2016 By the Numbers : March 17, 2017
Mar-14-17 02:58PM  Cleveland BioLabs, Inc. :CBLI-US: Earnings Analysis: 2016 By the Numbers : March 14, 2017 Capital Cube
02:58PM  Cleveland BioLabs, Inc. :CBLI-US: Earnings Analysis: 2016 By the Numbers : March 14, 2017
Feb-28-17 01:04PM  CLEVELAND BIOLABS INC Financials
Feb-22-17 04:21PM  CLEVELAND BIOLABS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exh -9.69%
04:15PM  Cleveland BioLabs Reports 2016 Financial Results and Development Progress Marketwired
Dec-07-16 11:24AM  ETFs with exposure to Cleveland BioLabs, Inc. : December 7, 2016 Capital Cube -7.43%
11:24AM  ETFs with exposure to Cleveland BioLabs, Inc. : December 7, 2016
Nov-15-16 11:56AM  Cleveland BioLabs, Inc. :CBLI-US: Earnings Analysis: Q3, 2016 By the Numbers : November 15, 2016 +7.05%
Nov-14-16 07:31AM  CLEVELAND BIOLABS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exh
07:30AM  Cleveland BioLabs Reports Third Quarter 2016 Financial Results and Development Progress Marketwired
Oct-11-16 08:46AM  CLEVELAND BIOLABS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Stateme
08:45AM  Cleveland BioLabs Announces a $1.1 Million Cost Realignment With the Department of Defense Marketwired
Sep-28-16 09:41AM  ETFs with exposure to Cleveland BioLabs, Inc. : September 28, 2016 Capital Cube
09:41AM  ETFs with exposure to Cleveland BioLabs, Inc. : September 28, 2016
Sep-12-16 10:38AM  ETFs with exposure to Cleveland BioLabs, Inc. : September 12, 2016
Aug-30-16 11:00AM  ETFs with exposure to Cleveland BioLabs, Inc. : August 30, 2016
Aug-19-16 12:43PM  ETFs with exposure to Cleveland BioLabs, Inc. : August 19, 2016
Aug-18-16 10:43AM  Cleveland BioLabs, Inc. :CBLI-US: Earnings Analysis: Q2, 2016 By the Numbers : August 18, 2016 Capital Cube
10:43AM  Cleveland BioLabs, Inc. :CBLI-US: Earnings Analysis: Q2, 2016 By the Numbers : August 18, 2016
Aug-15-16 08:42AM  CLEVELAND BIOLABS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exh -10.73%
08:30AM  Cleveland BioLabs Reports Second Quarter 2016 Financial Results and Development Progress Marketwired
Jul-22-16 04:22PM  CLEVELAND BIOLABS INC Files SEC form 8-K, Change in Directors or Principal Officers
Jul-21-16 06:05AM  CLEVELAND BIOLABS INC Files SEC form 8-K/A, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Sta -6.42%
Jul-19-16 12:08PM  ETFs with exposure to Cleveland BioLabs, Inc. : July 19, 2016
Jul-12-16 04:25PM  CLEVELAND BIOLABS INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Stand -10.17%
09:00AM  Cleveland BioLabs Announces Board Resignations Marketwired
May-17-16 12:26PM  Cleveland BioLabs, Inc. :CBLI-US: Earnings Analysis: Q1, 2016 By the Numbers
May-16-16 07:30AM  Cleveland BioLabs Reports First Quarter 2016 Financial Results and Development Progress Marketwired
May-12-16 02:40PM  22nd Century to begin cannabis research at new medical campus labs at bizjournals.com
May-06-16 05:55PM  CLEVELAND BIOLABS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibit
Apr-15-16 03:05PM  CLEVELAND BIOLABS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
Apr-04-16 07:30AM  Cleveland BioLabs Announces Webcast of Annual Meeting Marketwired
Mar-16-16 02:50PM  CLEVELAND BIOLABS INC Files SEC form 8-K, Other Events -19.40%
02:00PM  Cleveland BioLabs Provides Update on Pre-EUA Review of Entolimod as Radiation Countermeasure Marketwired
Feb-23-16 05:04PM  CLEVELAND BIOLABS INC Files SEC form 10-K, Annual Report
Feb-22-16 10:35AM  CLEVELAND BIOLABS INC Files SEC form 8-K, Results of Operations and Financial Condition
07:30AM  Cleveland BioLabs Reports 2015 Financial Results and Development Progress Marketwired
Feb-09-16 07:30AM  Entolimod Shown to Suppress Metastasis and Induce Immunity by Stimulating NK-Dendritic-CD8+ T cell Axis in Studies by Cleveland BioLabs and Roswell Park Cancer Institute Marketwired
Feb-02-16 08:00AM  Cleveland BioLabs Announces Start of Colorectal Cancer Study of Entolimod in Russian Federation Marketwired -5.13%
Jan-26-16 07:49AM  Cleveland BioLabs Announces Start of Phase 2 Study of CBLB612 in Russian Federation at noodls
07:30AM  Cleveland BioLabs Announces Start of Phase 2 Study of CBLB612 in Russian Federation Marketwired
Jan-22-16 03:25PM  Cleveland BioLabs Gets Orphan Status for Entolimod in EU +5.83%
Jan-21-16 07:30AM  Cleveland BioLabs Attains Orphan Drug Status From the EMA for Entolimod as a Radiation Countermeasure
Dec-24-15 01:04PM  CLEVELAND BIOLABS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a Material Defin
Dec-22-15 07:30AM  Cleveland BioLabs and Rusnano Make Additional Investments in Panacela Marketwired
Dec-16-15 01:16PM  Cleveland BioLabs, Inc. Earnings Analysis: Q3, 2015 By the Numbers
Dec-14-15 07:30AM  Entolimod Shown to Suppress Liver Metastases in Model of Ocular Melanoma in Collaborative Study by Cleveland BioLabs, Emory University and Roswell Park Cancer Institute Marketwired
Nov-30-15 07:30AM  Cleveland BioLabs Announces Expanded U.S. Patent Protection for Entolimod Marketwired
Nov-09-15 04:17PM  CLEVELAND BIOLABS INC Files SEC form 10-Q, Quarterly Report
Nov-05-15 07:31AM  CLEVELAND BIOLABS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exh
07:30AM  Cleveland BioLabs Reports Third Quarter 2015 Financial Results and Development Progress Marketwired
07:07AM  Q3 2015 Cleveland Biolabs Inc Earnings Release - Time Not Supplied
Oct-27-15 08:00AM  Cleveland BioLabs to Report Third Quarter 2015 Financial Results on November 5 Marketwired
Sep-21-15 07:31AM  CLEVELAND BIOLABS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
07:30AM  Department of Defense Grants Cleveland BioLabs Second Award for Advanced Development of Entolimod as a Medical Radiation Countermeasure Marketwired
Sep-17-15 10:39AM  Cleveland BioLabs, Inc. Earnings Q2, 2015
Sep-16-15 08:00AM  Cleveland BioLabs Announces Publication of Studies Demonstrating Efficacy of Entolimod as a Radiation Countermeasure up to 48 Hours After Exposure of Nonhuman Primates to Lethal Radiation Marketwired +7.13%
Sep-02-15 12:42PM  CLEVELAND BIOLABS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits +7.91%
11:48AM  Department of Defense Awards Cleveland BioLabs a $9.2 Million Contract for Advanced Development of Entolimod as a Medical Radiation Countermeasure Marketwired
08:00AM  Cleveland BioLabs to Present at Rodman & Renshaw 17th Annual Global Investment Conference Marketwired
Aug-18-15 08:00AM  Cleveland BioLabs Announces New Patents Strengthening Entolimod Portfolio Marketwired
Aug-14-15 08:10PM  10-Q for Cleveland BioLabs, Inc. at Company Spotlight
Aug-12-15 07:31AM  CLEVELAND BIOLABS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exh -18.24%
07:30AM  Cleveland BioLabs Reports Second Quarter 2015 Financial Results and Development Progress Marketwired
07:07AM  Q2 2015 Cleveland Biolabs Inc Earnings Release - Time Not Supplied
Aug-04-15 02:08PM  3 Breakout Stocks Under $10 Set to Soar at TheStreet
Jul-31-15 01:00PM  Cleveland BioLabs Announces Date Change for Second Quarter 2015 Financial Results Marketwired
Jul-28-15 01:33PM  3 Stocks Under $10 to Trade for Big Breakouts at TheStreet
Jul-21-15 02:03PM  3 Stocks Under $10 Triggering Breakout Trades at TheStreet +17.16%
07:30AM  Cleveland BioLabs to Report Second Quarter 2015 Financial Results on August 3 Marketwired
Jul-16-15 08:00AM  Cleveland BioLabs Announces Receipt of Letter From Nasdaq Confirming Compliance With Minimum Stockholders' Equity Requirement Marketwired
Jul-13-15 04:09PM  CLEVELAND BIOLABS INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Stand +8.73%
07:30AM  Cleveland BioLabs Announces Results of Phase 1 Study of CBLB612 in Russian Federation Marketwired
Jul-10-15 07:31AM  CLEVELAND BIOLABS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity Sec
07:30AM  Cleveland BioLabs Announces Board Appointments Marketwired
Jul-09-15 09:21AM  CLEVELAND BIOLABS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
09:15AM  Cleveland BioLabs Closes Private Placement With Strategic Investor for $25 Million Equity Financing Marketwired
Jul-07-15 04:07PM  CLEVELAND BIOLABS INC Files SEC form 8-K, Completion of Acquisition or Disposition of Assets
Jun-26-15 12:52PM  Xactly Corp (XTLY), AppFolio Inc (APPF), AlarmCom Hldg Inc (ALRM) In the Spotlights As They Go Public at Insider Monkey
12:32PM  Friday's Mid-Day Movers: Micron, Winnebago, Cleveland BioLabs And More
Jun-25-15 01:14PM  Thursday's Mid-Day Movers: Supreme Court's Obamacare Ruling Lifting Stocks +90.11%
11:51AM  Cleveland BioLabs (CBLI) Stock Spikes on $25 Million Equity Financing Agreement at TheStreet
07:01AM  CLEVELAND BIOLABS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
07:00AM  Cleveland BioLabs Enters Into Private Placement Agreement With Strategic Investor for $25 Million Equity Financing Marketwired
Jun-24-15 04:59PM  CLEVELAND BIOLABS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Changes in Control or Registran
Jun-15-15 07:30AM  Cleveland BioLabs Submits Pre-EUA Dossier for Entolimod to FDA Marketwired
Cleveland BioLabs, Inc., a biopharmaceutical company, develops novel approaches to activate the immune system and address various medical needs in the United States and the Russian Federation. The company's advanced product candidate is entolimod, a Toll-like receptor 5 (TLR5) agonist that is used to prevent death from acute radiation syndrome, and as an oncology drug. It is also developing CBLB612, a pharmacologically optimized synthetic molecule that structurally mimics naturally occurring lipopeptides of Mycoplasma, and activates NF-kB pro-survival and immunoregulatory signaling pathways; and Mobilan, a recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand. In addition, the company develops CBL0137, a small molecule with a multi-targeted mechanism of action used for the treatment of various types of cancer. Cleveland BioLabs, Inc. has strategic partnerships with The Cleveland Clinic and Roswell Park Cancer Institute. The company was founded in 2003 and is headquartered in Buffalo, New York.